# Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis

> **NCT01446211** · PHASE3 · TERMINATED · sponsor: **Nordic Pharma SAS** · enrollment: 4 (actual)

## Conditions studied

- Wegeners Granulomatosis

## Interventions

- **DRUG:** Gusperimus + glucocorticoids
- **DRUG:** cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids

## Key facts

- **NCT ID:** NCT01446211
- **Lead sponsor:** Nordic Pharma SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2012-11
- **Final completion:** 2015-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Change of design consideration
- **Last updated:** 2015-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01446211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01446211, "Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01446211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*